Welcome and Opening Remarks

10:30

Jill Biden, EdD  
First Lady of the United States

The Honorable Michael N. Castle*  
Chair Emeritus, Governor of Delaware, 1985-1992,  
U.S. Representative, 1993-2011

Mary Woolley*  
President and CEO, Research!America

Outsmarting a Global Health Threat: What will it take to keep AMR at bay?

10:45

Alok Patel, MD  
Pediatric Hospitalist, Lucile Packard Children’s Hospital; Special  
Correspondent, ABC News; Pediatric Content Advisor, MedScape;  
Host, NOVA Now Podcast, PBS

Santiago Gonzalez, MPH  
Senior Policy Advisor, Senator Michael Bennet (D-CO)

Stefano Bertuzzi, PhD, MPH  
CEO, American Society for Microbiology

Amanda Jezek  
Senior Vice President, Public Policy and Government  
Relations, Infectious Diseases Society of America

Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS  
Associate Professor of Medicine with the Division of Infectious Diseases and International Health, Duke University School of Medicine

Rita Livadas, PharmD  
Director of Public Affairs, BD

Living with a Rare Disease: Cystic Fibrosis

12:00

Gunner Esiason  
Patient Advocate, Boomer Esiason Foundation

Diagnosing Rare Diseases: A Parent’s Journey

12:23

Christina Hartman  
Vice President of External Affairs, The Assistance Fund

The Honorable Michael N. Castle*  
Chair Emeritus, Governor of Delaware, 1985-1992,  
U.S. Representative, 1993-2011

Mary Woolley*  
President and CEO, Research!America

Each year in the United States, more than 2 million people become infected with bacteria that are resistant to antibiotics, and at least 23,000 die as a result of these infections. Globally, an estimated 700,000 deaths per year are attributed to antimicrobial resistance (AMR). The WHO has declared that AMR is one of the top ten global public health threats facing humanity. Combating AMR requires innovation, not just to develop treatments that replace those compromised by AMR, but to slow the trajectory of AMR as much as possible, saving lives and creating space for those new treatments to come to fruition. This interactive roundtable discussion will focus on the latter imperative. What are the strategies that fall under the umbrella of AMR “stewardship?” Can we do more to slow the pace of resistance, and if so, how? How high are the stakes? How is stewardship success measured? What is the outlook absent new strategies and faster development of antimicrobial treatments?
The audience will join renowned leaders in science and technology to take a clear-eyed look at efforts to equip our nation with the S&T capabilities needed to out-innovate existential threats and stay globally competitive. Will current policy efforts to bolster U.S. S&T come to fruition? How do we ensure our nation can continue to successfully compete in the global economy while collaborating internationally to maximize S&T progress? The conversation will fully engage the audience on these critical questions and more.

Faster Rare Disease Progress is Within our Reach

Mary Woolley*
President and CEO, Research!America

Emil Kakkis, MD, PhD
Chief Executive Officer and President, Ultragenyx Pharmaceutical Inc.

Envision360: It Takes an Ecosystem

Michael Ybarra, MD
Vice President of Advocacy and Strategic Alliances and Chief of Medical Affairs, PhRMA

Fireside Chat: The Research Behind Healthcare Excellence

David Meyers, MD
Acting Director, Agency for Healthcare Research and Quality

Lisa Simpson, MB, BCh, MPH, FAAP
President and CEO, AcademyHealth

U.S. Science and Technology on the Front Lines

Sudip Parikh, PhD*
Chief Executive Officer; Executive Publisher, Science Family of Journals, American Association for the Advancement of Science

Sethuraman Panchanathan, PhD
Director, National Science Foundation

Kaye Husbands Fealing, PhD
Dean, Ivan Allen College of Liberal Arts, Georgia Institute of Technology

Mikael Dolsten, MD, PhD*
Chief Scientific Officer and President, Worldwide Research, Development, and Medical, Pfizer Inc

Marcia McNutt, PhD
President, National Academy of Sciences

Fireside Chat: Innovation Amplified: ARPA-H

Hallie Jackson
Senior Washington Correspondent, NBC News; Host, MSNBC’s “Hallie Jackson Reports”

Francis Collins, MD, PhD
Director, National Institutes of Health

Eric Lander, PhD
Director, Office of Science and Technology Policy; Science Advisor to the President

* Current or Emeritus Research!America Board Member
Chronic diseases and conditions have figured prominently into the COVID-19 pandemic, increasing the risk associated with and the toll the coronavirus has taken on Americans and populations across the globe. Beyond COVID-19, the human and fiscal costs of this constellation of health threats is staggering; according to the Milken Foundation, the annual economic impact on the U.S. of the seven most common chronic diseases is estimated to be $1.3 trillion, which could grow to approximately $6 trillion by 2050.

This discussion will focus on public and private sector-fueled progress against lupus and Alzheimer’s, two diseases emblematic of the challenges posed by chronic conditions, shedding light on how far we’ve come and how far we have yet to go to defeat them. What are the most promising developments against lupus and Alzheimer’s disease? What is the significance of the regulatory landscape? What role do patients play in determining the direction of progress against these threats?
Paige Winfield Cunningham
Editor, The Health 202, The Washington Post

Janine Austin Clayton, MD, FARVO
NIH Associate Director for Research on Women’s Health; Director, NIH Office of Research on Women’s Health

Joy Buie, PhD, MSCR, BSN, RN
Associate Director of Research, Lupus Foundation of America

Sherrita Dorsey, RN, MSN, FNP
Senior Director, Advocacy & Patient Engagement, Specialty Business Unit, GlaxoSmithKline

Stacy Holdsworth, PharmD
Senior Advisor, US Regulatory Policy & Strategy, Eli Lilly and Company

Ian Kremer, JD
Executive Director, Leaders Engaged on Alzheimer’s Disease (LEAD) Coalition

Ellie Dehoney
Vice President, Policy and Advocacy, Research!America

William N. Hait, MD, PhD*
Global Head, Johnson & Johnson Global External Innovation

John Siniff
Executive Vice President, Subject Matter; Former Opinion Editor, USA Today

Anthony S. Fauci, MD
Director, National Institute of Allergy and Infectious Diseases, NIH

Alexandra Colón-Rodríguez, PhD
Postdoctoral Scientist, Neurobiology, Physiology, and Behavior, University of California Davis

Lauren Powell, MPA, PhD
President & CEO, The Equitist, LLC; Vice President, US Health Equity & Community Wellness, Takeda Pharmaceuticals

Joel Beetsch, PhD
Vice President of Corporate Affairs, Eisai, Inc.

Faiza Siddiqui, PhD
Research Associate, Department of Internal Medicine, University of South Florida

Dana Acton
Director, Science Policy and Legislative Affairs, American Association for Cancer Research (AACR)

Kafui Dzirasa, MD, PhD*
K. Ranga Rama Krishnan Endowed Associate Professor of Psychiatry and Behavioral Sciences, Duke University Medical Center

Lauren Powell, MPA, PhD
President & CEO, The Equitist, LLC; Vice President, US Health Equity & Community Wellness, Takeda Pharmaceuticals

James Quinn, PhD
Neurology Research Fellow, Alzheimer’s Clinical & Translational Research Unit (ACTRU), Massachusetts General Hospital and Harvard Medical School

Andrea Morgan
Graduate Research Assistant, Behavioral and Systems Neuroscience Program, Oregon Health & Science University

Sarah Grace Dennis-Little, PhD
Postdoctoral Scholar, Department of Surgery, Medical University of South Carolina

Salvatore Aiello
MD/PhD Candidate, Rosalind Franklin University of Medicine & Science

Andrea Morgan
Graduate Research Assistant, Behavioral and Systems Neuroscience Program, Oregon Health & Science University

James Quinn, PhD
Neurology Research Fellow, Alzheimer’s Clinical & Translational Research Unit (ACTRU), Massachusetts General Hospital and Harvard Medical School

Faiza Siddiqui, PhD
Research Associate, Department of Internal Medicine, University of South Florida

* Current or Emeritus Research!America Board Member
DAY 3 - Defining the Path Forward
September 15

3:30
A Relatable Path to Uncommon Leadership: A Conversation with the Honorable Donna Shalala and Dr. Elias Zerhouni

Keila Miles, PhD
Community Features Coordinator, VanGuardSTEM

The Honorable Donna Shalala, PhD*
Professor, University of Miami; U.S. Secretary of Health and Human Services, 1983-2001; U.S. Representative, 2019-2021

Elias Zerhouni, MD*
Professor Emeritus, Radiology and Biomedical Engineering, Johns Hopkins University; Director, National Institutes of Health, 2002-2008

4:00
Virtual Networking Reception

Opening Discussion: What will it take to achieve health equity?

Mia Keys, MA, DrPH(c)
Chief of Staff, Office of Congresswoman Robin L. Kelly (IL-02)

10:45
The Challenge and Imperative of Advancing Diversity in Cancer Clinical Trials

Jeff Allen, PhD
President and CEO, Friends of Cancer Research

Peter C. Adamson, MD
Global Head, Oncology Development and Pediatric Innovation, Sanofi

11:00
Can We Truly Conquer Cancer?
The participants in this discussion will explore the path to progress against cancer from several different vantage points. Bringing together representatives from the patient community, the federal government, academia, and industry, the discussion will highlight the roles the public and private sector play in cancer-focused discovery, development, and delivery; hone in on the extraordinary potential inherent in breakthroughs such as immunology and CRISPR, and what those leaps in progress mean for the spectrum of cancer threats; shed light on the challenges that have rendered progress elusive against some forms of the disease such as glioblastoma and pancreatic cancer; and look at ways the horizon may be shifting (e.g., the possibility of new platforms that enable progress against multiple forms of cancer at once; the role of new clinical trial designs) as the fight to overcome cancer continues.

Jeff Allen, PhD
President and CEO, Friends of Cancer Research

Ned Sharpless, MD
Director, National Cancer Institute, NIH

Julia Beaver, MD
Chief of Medical Oncology, Oncology Center of Excellence; Deputy Director (Acting), Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA

John Carpten, PhD
Professor and Chair, Department of Translational Genomics; Director, Institute for Translational Genomics, Keck School of Medicine, University of Southern California

Jacqueline Corrigan-Curay, JD, MD
Principal Deputy Center Director, Center for Drug Evaluation and Research, FDA

Lisa Lacasse
President, American Cancer Society Cancer Action Network

David Reese, MD
Executive Vice President, Research and Development, Amgen

5
* Current or Emeritus Research!America Board Member
12:30 Diversity, Equity, & Inclusion: Tracking Progress and Measuring Success

The roundtable participants — with audience input and a focus on the health-focused R&D workforce and workplace — will share strategies for advancing and evaluating diversity, equity, and inclusion (DEI). What are the best practices for advancing workforce and workplace DEI? Are there approaches that appeared to hold promise, but have proven ineffective? Are current definitions of DEI too broad or too narrow to promote the wellbeing of individuals across the R&D workforce? What quantitative and qualitative measures accurately capture DEI progress? What are the key attributes of a diverse, equitable and inclusive workforce and workplace?

Jessica Bylander
Senior Editor and Correspondent, Health Affairs

Robert Sellers, PhD
Vice Provost for Equity & Inclusion and Chief Diversity Officer, Charles D. Moody Collegiate Professor of Psychology, University of Michigan

Esther C. Nolton, PhD, MEd
Program Officer, Evaluation and Analysis, Patient-Centered Outcomes Research Institute

1:30 ENVISION 360: Defining Success in Clinical Trial Diversity

Rachael Fones
Director, Government & Public Affairs, IQVIA

1:45 A View from the Problem Solvers Caucus

Jenny Luray
Vice President of Strategy and Communications, Research!America

The Honorable Josh Gottheimer
U.S. Representative (D-NJ-05)

The Honorable Charlie Dent*
Executive Director & Vice President, The Aspen Institute, Senior Policy Advisor, DLA Piper LLP, U.S. Representative, 2005-2018

2:00 COVID-19 Vaccines: A Conversation with FDA’s Peter Marks

Amy Comstock Rick, JD*
President and CEO, Food and Drug Law Institute

Peter Marks, MD
Director, Center for Biologics Evaluation & Research, FDA

2:20 Envision360: Global Threats Cross Borders: Dengue Fever

Derek Wallace, MBBS
Vice President and Global Dengue Program Head, Vaccine Business Unit, Takeda Pharmaceuticals

3:00 ENVISION360: Championing Self-Care

Laurie Hernandez
Olympic Gymnastics Champion and One Mind Ambassador

* Current or Emeritus Research!America Board Member
Reaching for More: Access, Equity, and Innovation

What’s important in health care? Medical and public health progress that bring about safe and effective solutions; affordability for individual patients and for our healthcare system as a whole; access to the benefits of medical progress; and health equity, which depends on progress, affordability, and access, are certainly cornerstones of an effective health care system. Looking at prescription drugs as one piece of the health care puzzle, this interactive roundtable discussion will explore the challenges, imperatives, and options for simultaneously advancing progress, affordability, access, and equity.

Mark McClellan, MD, PhD*
Director, Robert J. Margolis Center for Health Policy, Duke University; Former Administrator, CMS, 2004-2006; Former Commissioner, FDA, 2002-2004

Peter Pronovost, MD, PhD
Chief Quality & Clinical Transformation Officer, University Hospitals; Professor, Department of Anesthesiology and Critical Care Medicine, School of Medicine and School of Nursing, Case Western Reserve University

Mark Reisenauer
President, Astellas Pharma US

Gary Puckrein, PhD
President and Chief Executive Officer, National Minority Quality Forum

Cynthia Zagieboylo*
President and Chief Executive Officer, National MS Society

* Current or Emeritus Research!America Board Member

THANK YOU TO OUR SPONSORS!